Out of 712 patients, 515 (72%) had tumor tissue available for molecular testing; 37% (188/515) of tumors were analyzed using NGS methods, while 59% (306/515) were tested only for EGFR and ALK (Figure 1). The gene discussed is ALK; the disease is neoplasm.